Sign In
Buy CGEN
$2.34
-0.0700 (-2.90%)
At Close: Aug 10, 2026
Compugen Ltd. (CGEN) Q1 2020 Earnings Call Transcript
02:00am, Thursday, 07'th May 2020
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN)Q1 2020 Earnings CallMay 6, 2020, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Opera
Compugen Reports First Quarter 2020 Results
11:00am, Wednesday, 06'th May 2020
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2020.
Compugen shares are trading lower after the company reported Q1 earnings results.
12:00am, Wednesday, 06'th May 2020Can This Biotech Shed New Light on Cancer Immunotherapies?
03:57pm, Monday, 04'th May 2020
Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.
What Makes Compugen (CGEN) a New Strong Buy Stock
04:00pm, Thursday, 30'th Apr 2020
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Top Analyst Upgrades and Downgrades: AT&T, Cognex, Disney, J&J, Keurig Dr Pepper, PayPal, Roku, Shopify, Square, Valero and More
01:02pm, Tuesday, 28'th Apr 2020
Tuesday's top analyst upgrades and downgrades included AT&T, Cognex, Johnson & Johnson, Keurig Dr Pepper, PayPal, Roku, Shopify, Square, Valero Energy and Walt Disney.
Compugen sees "encouraging signals" from early-stage cancer trial
10:05am, Monday, 27'th Apr 2020
Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have exhau
Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting
10:00am, Monday, 27'th Apr 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, will present updated results from its ongoing Phase 1 dose escalation study of
Compugen to Present Updated Data From its Ongoing Phase 1 Trial of COM701 at 11:45am ET Today
12:00am, Monday, 27'th Apr 2020The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
08:37pm, Sunday, 26'th Apr 2020
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week,...
Stocks To Watch: Tech Powerhouses Lead Earnings Blitz
12:30pm, Saturday, 25'th Apr 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
3 Monster Growth Stocks Gearing up for Gains
02:50pm, Friday, 24'th Apr 2020
Just when it looked like time to throw in the towel, the market pulled through and delivered a win. Stabilizing crude oil prices, a few better-than-expected earnings reports as well as the possibility
3 Monster Growth Stocks Gearing up for Gains
02:47pm, Friday, 24'th Apr 2020
Just when it looked like time to throw in the towel, the market pulled through and delivered a win. Stabilizing crude oil prices, a few
Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020
11:00am, Thursday, 23'rd Apr 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2020 financial
